Literature DB >> 11270475

Prevalence and clinical relevance of serum anti-p53 antibodies in patients with cholangiocarcinoma.

P Tangkijvanich1, K Kasemsupatana, A Janchai, P Kullavanijaya, A Theamboonlers, Y Poovorawan.   

Abstract

Cholangiocarcinoma (CCA) constitutes carcinoma of the bile duct found at a high prevalence in northeastern Thailand. In the present study, we examined the sera of altogether 82 Thai CCA patients for the presence of anti-p53 antibodies in order to investigate a role of the tumor suppressor gene, p53 in the carcinogenesis. Our results revealed anti-p53 antibodies in 7.3% of the cases tested, which conforms to the prevalence rate of p53 gene mutation recently reported at 5% among Thai patients. With limited number of the patients, anti-p53 antibodies were rapidly detected more frequently among patients with peripheral tumors than those with central tumors. However, further studies is required to establish significance and prognostic value of the antibodies in the context of CCA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11270475

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  2 in total

1.  Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.

Authors:  Rei Okada; Hideaki Shimada; Yuichiro Otsuka; Masaru Tsuchiya; Jun Ishii; Toshio Katagiri; Tetsuya Maeda; Yoshihisa Kubota; Tetsuo Nemoto; Hironori Kaneko
Journal:  Surg Today       Date:  2017-05-15       Impact factor: 2.549

Review 2.  Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.

Authors:  Aravind Suppiah; John Greenman
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.